The honest bottom line comes before the detail: the human evidence on delta sleep-inducing peptide is thin, roughly four decades old, and largely unreplicated, and it does not establish the compound as an effective sleep agent. Nearly the whole record was published between 1977 and the early 1990s across studies enrolling a handful to a couple of dozen participants, with no receptor identified and no marketing authorization anywhere. The distinction matters practically, because an unresolved research question and a validated therapy carry very different risks, and DSIP sits in the first category.
The human evidence base for DSIP consists of roughly a dozen to two dozen small studies published between 1977 and the early 1990s, with no identified receptor, no adequately powered randomized placebo-controlled trial, and no marketing authorization from any major medicines regulator.
Counted carefully, the published human record runs to roughly a dozen to two dozen papers, nearly all appearing between 1977 and the early 1990s, with a large share carrying the same Basel-linked investigators who characterized the peptide in the first place. Sample size is the defining feature: typical studies enrolled from a handful of subjects up to ten or twenty, and nothing in the literature approaches the scale of even a small modern phase 2 trial.
No published human study of delta sleep-inducing peptide enrolled more than roughly twenty participants, and none appears in ClinicalTrials.gov or a comparable registry, since mandatory registration postdates the research by a decade or more.
The peptide is named for an electroencephalographic phenomenon, and the electroencephalographic evidence is the weakest part of the case. Polysomnography measures to the epoch what a sleep diary can only estimate, and applied to DSIP in humans it produced a split picture: some reports of shorter sleep latency and better sleep efficiency, others showing participants rating their sleep as improved while the recordings registered no significant change. Insomnia research in general is known for divergence between subjective and objective measures, so a subjective-only gain is not automatically meaningless, but in a literature this small the objective layer was the only thing that could have corroborated the reports.
| Measure | Subjective report | Polysomnography |
|---|---|---|
| Sleep latency | Described as shorter | Modest reductions in some reports |
| Sleep efficiency | Rated as improved | Improved in some, unchanged in others |
| Delta-wave power | Implied by the compound's name | Not consistently demonstrated |
| Timing of gains | Reported over following days | Not seen on the dosing night |
Human polysomnography never consistently showed the increase in delta-wave activity that gives delta sleep-inducing peptide its name, and in several reports participants rated their sleep as better while the recordings showed no significant change.
Weaknesses are usually listed one at a time and weighed one at a time, which understates the problem here, because five of them compound. A crossover trial with twelve to twenty participants can detect only a large effect, so a null result proves nothing and a positive result sits one or two responders away from disappearing. The practical consequence is that these studies cannot be pooled at all, which is a large part of why no systematic review of DSIP for sleep exists.
The DSIP sleep studies differ too much in population, dose, route, and endpoint to be pooled, so no meta-analysis and no systematic review of the compound for sleep exists.
The founding experiment explains most of the difficulty. Monnier's group stimulated a donor rabbit's thalamus into delta-wave sleep and transferred its cerebral venous blood to a recipient, whose electroencephalogram shifted toward delta, which supports the claim that something transferable was present but not that the nonapeptide later purified from that dialysate was the agent responsible. When other laboratories administered synthetic DSIP, the results scattered badly: some found the reported effect, some found nothing, and some observed the opposite, including increased arousal or locomotor activity depending on species, dose, and circadian phase.
Reviewing the accumulated work in the mid-1980s, Graf and Kastin concluded that DSIP's various physiological functions and its possible mechanism of action remained to be established, and that assessment was never overturned.
Placed side by side, the gap is not a matter of degree but of category. An approved hypnotic arrives on the back of multiple randomized, double-blind, placebo-controlled phase 3 trials enrolling hundreds to well over a thousand participants each, with endpoints declared before the first dose and a safety database built from thousands of patient-months. Roughly a dozen small studies, mostly from one group, with no pre-specified endpoints and no independent replication, is what the field today treats as grounds for designing a proper trial, not as evidence of efficacy.
| Criterion | Approved hypnotics | DSIP |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled phase 3 | Small crossover and open studies |
| Enrollment per trial | Hundreds to over a thousand | A handful to roughly twenty |
| Endpoint pre-specification | Declared and registered before dosing | None |
| Independent replication | Multiple sites and sponsors | Absent |
| Systematic review | Present, with meta-analyses | None exists |
Cognitive behavioural therapy for insomnia is supported by dozens of randomized trials and several meta-analyses and is the first-line recommendation in major clinical guidelines, while DSIP has no systematic review, no meta-analysis, and no adequately powered trial of any kind.
DSIP is a short, unprotected peptide and behaves like one: roughly 850 daltons across nine residues, with no modifications shielding it from proteolysis, so circulating peptidases clear it within minutes. That profile collides with the central efficacy claim, since a molecule present in plasma for minutes and reaching the central nervous system only in part does not obviously account for sleep improvements reported to appear days after administration.
Measured plasma half-lives of DSIP in dogs, a monkey, and rats fall on the order of a few minutes, and the downstream-cascade explanation proposed for effects lasting days was never tested, since no receptor, second messenger, or downstream marker was ever identified.
No regulator has. DSIP holds no marketing authorization for sleep or for anything else from the United States Food and Drug Administration, the European Medicines Agency, or any comparable national authority, and it has never been the subject of a completed regulatory review for a sleep indication. The reason is procedural rather than mysterious: regulators evaluate what sponsors submit, and no sponsor ever assembled a dossier, because the research stopped decades before one would have been needed.
Absence of approval for DSIP reflects absence of submission rather than a regulatory judgment of harm, so no authority has found the compound either safe or effective for sleep.
The field walked away from DSIP rather than rejecting it, and the difference carries weight, because abandonment and refutation support different conclusions. Nobody ran the decisive negative trial. The question was closed by attrition as the bar for a credible signalling molecule rose past anything DSIP could supply.
Research on DSIP stopped by attrition rather than refutation, and forty years of silence in the journals, along with the compound's later reappearance in gray-market channels, is not a finding in either direction.
Settling this would take a sequence rather than a single study, and the sequence is not scientifically hard to specify. The obstacle is economic: the sequence has been in the public domain since 1977 and cannot support composition-of-matter protection, so no commercial sponsor can recover the tens of millions such a program costs, and public funders comparing it against targets with an identified receptor will reasonably fund the latter.
Detecting the modest effect the historical studies gestured at would require participants in the low hundreds rather than the low tens, and until a funder covers that cost, the accurate description of DSIP and sleep is unproven rather than promising.
Educational use only. This article describes what the published scientific and clinical literature reports about DSIP. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
